Clinical efficacy of zanolimumab (HuMax-CD4): Two phase 2 studies in refractory cutaneous T-cell lymphoma

Youn H. Kim, Madeleine Duvic, Erik Obitz, Robert Gniadecki, Lars Iversen, Anders Österborg, Sean Whittaker, Timothy M. Illidge, Thomas Schwarz, Roland Kaufmann, Kevin Cooper, Kim M. Knudsen, Steen Lisby, Ole Baadsgaard, Susan J. Knox

    Research output: Contribution to journalArticlepeer-review


    The efficacy and safety of zanolimumab in patients with refractory cutaneous Tcell lymphoma (CTCL) have been assessed in two phase 2, multicenter, prospective, open-label, uncontrolled clinical studies. Patients with treatment refractory CD4+ CTCL (mycosis fungoides [MF], n = 38; Sézary syndrome [SS], n = 9) received 17 weekly infusions of zanolimumab (early-stage patients, 280 and 560 mg; advanced-stage patients, 280 and 980 mg). The primary end point was objective response (OR) as assessed by composite assessment of index lesion disease activity score. Secondary end points included physician's global assessment (PGA), time to response, response duration, and time to progression. ORs were recorded for patients in both CTCL types (MF, 13 ORs; SS, 2 ORs). In the high-dose groups (560 and 980 mg dose groups), a response rate of 56% was obtained with a median response of 81 weeks. Adverse events reported most frequently included low-grade infections and eczematous dermatitis. Zanolimumab showed marked clinical efficacy in the treatment of patients with refractory MF, with early onset of response, high response rate, and durable responses. The treatment was well tolerated with no dose-related toxicity other than the targeted depletion of peripheral T cells. A pivotal study has been initiated based on these findings. © 2007 by The American Society of Hematology.
    Original languageEnglish
    Pages (from-to)4655-4662
    Number of pages7
    Issue number11
    Publication statusPublished - 1 Jun 2007


    • Adult
    • Aged
    • Aged, 80 and over
    • adverse effects: Antibodies, Monoclonal
    • chemistry: Antigens, CD4
    • Female
    • Humans
    • methods: Immunotherapy
    • therapy: Lymphoma, T-Cell, Cutaneous
    • Male
    • Middle Aged
    • therapy: Mycosis Fungoides
    • Prospective Studies
    • therapy: Sezary Syndrome
    • therapy: Skin Neoplasms


    Dive into the research topics of 'Clinical efficacy of zanolimumab (HuMax-CD4): Two phase 2 studies in refractory cutaneous T-cell lymphoma'. Together they form a unique fingerprint.

    Cite this